An expert from the Duke University School of Medicine describes how the FDA approval of tucatinib plus trastuzumab in HER2-positive metastatic colorectal cancer will improve access to treatment.
Approval Alert | Tucatinib Plus Trastuzumab for Advanced HER2+ Metastatic CRC
The FDA based its accelerated approval of tucatinib and trastuzumab combination therapy for HER2-positive metastatic colorectal cancer on results from the phase 2 MOUNTAINEER trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Ruxolitinib Tablets for Hematologic Malignancies
2
Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer
3
How Effective and Safe is EUS-Guided Alpha DaRT in Pancreatic Cancer?
4
SLN Surgery Omission Does Not Increase Radiotherapy Use in Breast Cancer
5